Emma Walmsley and Giovanni Caforio
Emma Walmsley and Giovanni Caforio led two of the world’s biggest drug companies during the same years. Walmsley became the first woman to lead a major global pharmaceutical company when she took over GSK in 2017. Caforio ran Bristol Myers Squibb (BMS) from 2015 to 2023 and later became chair of Swiss drug giant Novartis.
There’s no known close personal relationship between them, but they were peers and rivals in the same industry for years. This guide compares Emma Walmsley and Giovanni Caforio across their careers, strategies, and legacies.

Emma Walmsley and Giovanni Caforio at a Glance
| Detail | Emma Walmsley | Giovanni Caforio |
|---|---|---|
| Full name | Emma Natasha Walmsley | Giovanni Caforio |
| Born | June 1969, Barrow-in-Furness, England | 1964, Italy |
| Age | 57 (as of November 2026) | About 62 (as of November 2026) |
| Education | Christ Church, University of Oxford (MA in classics and modern languages) | Trained as a physician in Italy |
| Company | GSK | Bristol Myers Squibb, then Novartis |
| Top role | CEO of GSK (2017 to 2025) | CEO of BMS (2015 to 2023); chair of Novartis (from 2025) |
| Big move | Spinning off Haleon (2022) | Buying Celgene (2019) |
| Other boards | Microsoft | Novartis |
Who Is Emma Walmsley?
Emma Walmsley grew up in England, the daughter of a Royal Navy officer. She studied classics and modern languages at Christ Church, Oxford. She spent 17 years at L’Oréal in marketing and management roles in Paris, London, New York, and Shanghai.
She joined GSK in 2010 to lead its consumer health business. In April 2017, she became CEO, the first woman to lead one of the world’s largest drugmakers. She focused GSK on vaccines and specialty medicines, cut costs, and invested in research.
Her biggest move was splitting GSK into two companies. In 2022, GSK spun off its consumer health business as Haleon, home to brands like Sensodyne, Advil, and Centrum. GSK also defended against an unwanted takeover approach from Unilever for the consumer unit. Under her leadership, GSK’s shingles vaccine Shingrix became a blockbuster, and the company launched an RSV vaccine, Arexvy.
She also joined Microsoft’s board in 2019. In September 2025, GSK announced she would step down at the end of 2025. Luke Miels, the company’s chief commercial officer, succeeded her as CEO on January 1, 2026.
Who Is Giovanni Caforio?
Giovanni Caforio was born in Italy and trained as a physician. He holds Italian and US citizenship and speaks several languages. He began his career at Abbott Laboratories before joining BMS in 2000.
He held leadership roles across Europe and the United States, including running BMS’s US business and its oncology work. He became CEO in May 2015 and chairman in 2017.
His biggest move was buying Celgene for about $74 billion in 2019, one of the largest drug deals ever. The deal added cancer drugs like Revlimid and blood disease treatments. BMS also grew its immuno oncology drug Opdivo. He stepped down as CEO in November 2023, handing the job to Chris Boerner, and left the BMS board in 2024. Novartis then nominated him as its chair, and he was elected at the company’s 2025 annual meeting, succeeding Jörg Reinhardt.
What Connects Emma Walmsley and Giovanni Caforio?
There’s no known close friendship between Emma Walmsley and Giovanni Caforio. But they share many links:
- Same era: Both led top drug companies from the mid 2010s through the early 2020s.
- Industry peers: Both took part in industry groups and policy debates on drug pricing and research.
- Big reshaping: Walmsley split GSK, and Caforio transformed BMS through Celgene.
- Pandemic leadership: Both led their companies through COVID-19.
- Global careers: Both worked in many countries before becoming CEO.
Career Comparison
| Area | Emma Walmsley | Giovanni Caforio |
|---|---|---|
| Background | Consumer goods marketing | Medicine |
| Early career | L’Oréal | Abbott |
| Became CEO | 2017 | 2015 |
| Signature deal | Haleon spinoff | Celgene purchase |
| Next role | Left GSK at the end of 2025 | Chair of Novartis |
How Each Led
Walmsley was known for discipline and focus. Coming from consumer goods, she brought strong marketing and operations skills. Some investors questioned GSK’s research pipeline early in her tenure, but she pushed to strengthen it with new vaccines and specialty drugs.
Caforio was known for scientific understanding and bold deals. His medical training helped him judge research programs. The Celgene deal was risky, but it made BMS one of the largest cancer drug companies in the world.
Similarities
- Top of big pharma: Both led companies worth tens of billions of dollars.
- Transformers: Both changed their companies’ shape.
- International: Both are multilingual global executives.
Differences
| Area | Emma Walmsley | Giovanni Caforio |
|---|---|---|
| Training | Classics and languages | Medicine |
| Country | United Kingdom | Italy and United States |
| Main strategy | Splitting the company | Buying a rival |
| Gender milestone | First woman to lead a top drugmaker | Not applicable |
Wealth and Pay
Both earned large pay packages. Walmsley’s yearly pay at GSK was often reported at about £10 million or more in strong years. Caforio’s pay at BMS was often reported at about $20 million or more. Neither is a billionaire, and their exact net worths are not public.
Personal Lives
Walmsley is married to David Owen and has four children. She has spoken about balancing a demanding career with family life. Caforio keeps his family life private and has lived mainly in the United States during his BMS years.
Timeline at a Glance
| Year | Event |
|---|---|
| 2000 | Caforio joins BMS |
| 2010 | Walmsley joins GSK |
| 2015 | Caforio becomes BMS CEO |
| 2017 | Walmsley becomes GSK CEO |
| 2019 | BMS buys Celgene; Walmsley joins Microsoft’s board |
| 2022 | GSK spins off Haleon |
| 2023 | Caforio steps down as BMS CEO |
| 2025 | Caforio becomes Novartis chair; Walmsley leaves GSK at year end |
| 2026 | Luke Miels becomes GSK CEO |
Lessons From Their Careers
- Know when to split or combine. Walmsley split GSK, and Caforio combined BMS with Celgene.
- Bring outside skills. Walmsley’s consumer background helped her lead differently.
- Use expertise. Caforio’s medical training guided his choices.
Why People Compare Them
People pair these names because both were leading pharma CEOs at the same time. Comparing them shows two different ways to reshape a drug company. For another look at how executives from different corners of business compare, see our guide to David Einhorn and Kathy Warden.
Where They Stand in 2026
Walmsley has left GSK after nearly nine years as CEO and remains on Microsoft’s board. Caforio chairs Novartis, one of the world’s biggest drugmakers.
Final Comparison
Walmsley broke a glass ceiling and refocused GSK on medicines and vaccines. Caforio used a giant deal to make BMS a cancer drug leader and moved on to chair Novartis. Both shaped the industry during a time of fast change.
Quick Verdict
Walmsley is a pioneer for women in pharma leadership. Caforio is a doctor turned dealmaker who now guides one of Europe’s top drug companies.
Fun Facts
- Walmsley worked at L’Oréal for 17 years.
- Caforio is a trained physician.
- BMS paid about $74 billion for Celgene.
- GSK’s Haleon spinoff created a major consumer health company.
Challenges They Faced
Walmsley faced pressure from activist investors, including Elliott Management, which pushed GSK in 2021 to improve its drug pipeline and reconsider its leadership. She kept her job and delivered the Haleon spinoff. GSK also faced lawsuits in the United States over the heartburn drug Zantac, which it largely settled in 2024.
Caforio faced questions about whether BMS paid too much for Celgene, especially as key drugs like Revlimid faced generic competition. He also dealt with the coming loss of patent protection on other top sellers. His team invested in new drug areas, including heart and brain medicines, to replace that lost revenue.
How to Learn More
GSK’s and BMS’s annual reports explain the strategies each leader followed. Industry outlets like Fierce Pharma, BioSpace, and Endpoints News covered both executives closely. Novartis’s website lists Caforio’s current role and board work.
Quick Fact Check
Walmsley’s successor, Luke Miels, joined GSK from AstraZeneca in 2017. Caforio’s successor at BMS, Chris Boerner, had been the company’s chief operating officer.
Why People Watch Them
Both leaders remain important voices in global health. Walmsley’s move to step down drew wide attention because she was a role model for women in business. Caforio’s role at Novartis keeps him at the center of one of Europe’s largest companies.
Frequently Asked Questions
Do Emma Walmsley and Giovanni Caforio know each other? They were industry peers, but there’s no known close personal relationship.
Is Emma Walmsley still GSK’s CEO? No. She stepped down at the end of 2025, and Luke Miels took over on January 1, 2026.
What is Giovanni Caforio doing now? He is the chair of Novartis.
Who was the first woman to lead a major drug company? Emma Walmsley, at GSK in 2017.
Final Thoughts
Emma Walmsley and Giovanni Caforio led two drug giants through a time of big change. Walmsley split GSK to sharpen its focus, while Caforio built BMS through a huge merger. Both remain influential voices in global health care.
Key Takeaways
- Emma Walmsley and Giovanni Caforio were peer drug company CEOs for years.
- Walmsley led GSK from 2017 to 2025 and spun off Haleon in 2022.
- Caforio led BMS from 2015 to 2023 and bought Celgene for about $74 billion.
- Caforio became Novartis chair in 2025.
- Emma Walmsley and Giovanni Caforio both reshaped their companies.
- Luke Miels succeeded Walmsley as GSK CEO in January 2026.